-
BraTS-PEDs: Results of the Multi-Consortium International Pediatric Brain Tumor Segmentation Challenge 2023
Authors:
Anahita Fathi Kazerooni,
Nastaran Khalili,
Xinyang Liu,
Debanjan Haldar,
Zhifan Jiang,
Anna Zapaishchykova,
Julija Pavaine,
Lubdha M. Shah,
Blaise V. Jones,
Nakul Sheth,
Sanjay P. Prabhu,
Aaron S. McAllister,
Wenxin Tu,
Khanak K. Nandolia,
Andres F. Rodriguez,
Ibraheem Salman Shaikh,
Mariana Sanchez Montano,
Hollie Anne Lai,
Maruf Adewole,
Jake Albrecht,
Udunna Anazodo,
Hannah Anderson,
Syed Muhammed Anwar,
Alejandro Aristizabal,
Sina Bagheri
, et al. (55 additional authors not shown)
Abstract:
Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 cha…
▽ More
Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 challenge, the first Brain Tumor Segmentation (BraTS) challenge focused on pediatric brain tumors. This challenge utilized data acquired from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. BraTS-PEDs 2023 aimed to evaluate volumetric segmentation algorithms for pediatric brain gliomas from magnetic resonance imaging using standardized quantitative performance evaluation metrics employed across the BraTS 2023 challenges. The top-performing AI approaches for pediatric tumor analysis included ensembles of nnU-Net and Swin UNETR, Auto3DSeg, or nnU-Net with a self-supervised framework. The BraTSPEDs 2023 challenge fostered collaboration between clinicians (neuro-oncologists, neuroradiologists) and AI/imaging scientists, promoting faster data sharing and the development of automated volumetric analysis techniques. These advancements could significantly benefit clinical trials and improve the care of children with brain tumors.
△ Less
Submitted 16 July, 2024; v1 submitted 11 July, 2024;
originally announced July 2024.
-
Analysis of the BraTS 2023 Intracranial Meningioma Segmentation Challenge
Authors:
Dominic LaBella,
Ujjwal Baid,
Omaditya Khanna,
Shan McBurney-Lin,
Ryan McLean,
Pierre Nedelec,
Arif Rashid,
Nourel Hoda Tahon,
Talissa Altes,
Radhika Bhalerao,
Yaseen Dhemesh,
Devon Godfrey,
Fathi Hilal,
Scott Floyd,
Anastasia Janas,
Anahita Fathi Kazerooni,
John Kirkpatrick,
Collin Kent,
Florian Kofler,
Kevin Leu,
Nazanin Maleki,
Bjoern Menze,
Maxence Pajot,
Zachary J. Reitman,
Jeffrey D. Rudie
, et al. (96 additional authors not shown)
Abstract:
We describe the design and results from the BraTS 2023 Intracranial Meningioma Segmentation Challenge. The BraTS Meningioma Challenge differed from prior BraTS Glioma challenges in that it focused on meningiomas, which are typically benign extra-axial tumors with diverse radiologic and anatomical presentation and a propensity for multiplicity. Nine participating teams each developed deep-learning…
▽ More
We describe the design and results from the BraTS 2023 Intracranial Meningioma Segmentation Challenge. The BraTS Meningioma Challenge differed from prior BraTS Glioma challenges in that it focused on meningiomas, which are typically benign extra-axial tumors with diverse radiologic and anatomical presentation and a propensity for multiplicity. Nine participating teams each developed deep-learning automated segmentation models using image data from the largest multi-institutional systematically expert annotated multilabel multi-sequence meningioma MRI dataset to date, which included 1000 training set cases, 141 validation set cases, and 283 hidden test set cases. Each case included T2, T2/FLAIR, T1, and T1Gd brain MRI sequences with associated tumor compartment labels delineating enhancing tumor, non-enhancing tumor, and surrounding non-enhancing T2/FLAIR hyperintensity. Participant automated segmentation models were evaluated and ranked based on a scoring system evaluating lesion-wise metrics including dice similarity coefficient (DSC) and 95% Hausdorff Distance. The top ranked team had a lesion-wise median dice similarity coefficient (DSC) of 0.976, 0.976, and 0.964 for enhancing tumor, tumor core, and whole tumor, respectively and a corresponding average DSC of 0.899, 0.904, and 0.871, respectively. These results serve as state-of-the-art benchmarks for future pre-operative meningioma automated segmentation algorithms. Additionally, we found that 1286 of 1424 cases (90.3%) had at least 1 compartment voxel abutting the edge of the skull-stripped image edge, which requires further investigation into optimal pre-processing face anonymization steps.
△ Less
Submitted 15 May, 2024;
originally announced May 2024.
-
The Brain Tumor Segmentation in Pediatrics (BraTS-PEDs) Challenge: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)
Authors:
Anahita Fathi Kazerooni,
Nastaran Khalili,
Xinyang Liu,
Deep Gandhi,
Zhifan Jiang,
Syed Muhammed Anwar,
Jake Albrecht,
Maruf Adewole,
Udunna Anazodo,
Hannah Anderson,
Ujjwal Baid,
Timothy Bergquist,
Austin J. Borja,
Evan Calabrese,
Verena Chung,
Gian-Marco Conte,
Farouk Dako,
James Eddy,
Ivan Ezhov,
Ariana Familiar,
Keyvan Farahani,
Andrea Franson,
Anurag Gottipati,
Shuvanjan Haldar,
Juan Eugenio Iglesias
, et al. (46 additional authors not shown)
Abstract:
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. Here we pr…
▽ More
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge, focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors.
△ Less
Submitted 11 July, 2024; v1 submitted 23 April, 2024;
originally announced April 2024.
-
The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI
Authors:
Ahmed W. Moawad,
Anastasia Janas,
Ujjwal Baid,
Divya Ramakrishnan,
Rachit Saluja,
Nader Ashraf,
Leon Jekel,
Raisa Amiruddin,
Maruf Adewole,
Jake Albrecht,
Udunna Anazodo,
Sanjay Aneja,
Syed Muhammad Anwar,
Timothy Bergquist,
Evan Calabrese,
Veronica Chiang,
Verena Chung,
Gian Marco Marco Conte,
Farouk Dako,
James Eddy,
Ivan Ezhov,
Ariana Familiar,
Keyvan Farahani,
Juan Eugenio Iglesias,
Zhifan Jiang
, et al. (206 additional authors not shown)
Abstract:
The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and chara…
▽ More
The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and characterizes the challenging cases that impacted the performance of the winning algorithms. Untreated brain metastases on standard anatomic MRI sequences (T1, T2, FLAIR, T1PG) from eight contributed international datasets were annotated in stepwise method: published UNET algorithms, student, neuroradiologist, final approver neuroradiologist. Segmentations were ranked based on lesion-wise Dice and Hausdorff distance (HD95) scores. False positives (FP) and false negatives (FN) were rigorously penalized, receiving a score of 0 for Dice and a fixed penalty of 374 for HD95. Eight datasets comprising 1303 studies were annotated, with 402 studies (3076 lesions) released on Synapse as publicly available datasets to challenge competitors. Additionally, 31 studies (139 lesions) were held out for validation, and 59 studies (218 lesions) were used for testing. Segmentation accuracy was measured as rank across subjects, with the winning team achieving a LesionWise mean score of 7.9. Common errors among the leading teams included false negatives for small lesions and misregistration of masks in space.The BraTS-METS 2023 challenge successfully curated well-annotated, diverse datasets and identified common errors, facilitating the translation of BM segmentation across varied clinical environments and providing personalized volumetric reports to patients undergoing BM treatment.
△ Less
Submitted 17 June, 2024; v1 submitted 1 June, 2023;
originally announced June 2023.
-
The Brain Tumor Segmentation (BraTS) Challenge 2023: Glioma Segmentation in Sub-Saharan Africa Patient Population (BraTS-Africa)
Authors:
Maruf Adewole,
Jeffrey D. Rudie,
Anu Gbadamosi,
Oluyemisi Toyobo,
Confidence Raymond,
Dong Zhang,
Olubukola Omidiji,
Rachel Akinola,
Mohammad Abba Suwaid,
Adaobi Emegoakor,
Nancy Ojo,
Kenneth Aguh,
Chinasa Kalaiwo,
Gabriel Babatunde,
Afolabi Ogunleye,
Yewande Gbadamosi,
Kator Iorpagher,
Evan Calabrese,
Mariam Aboian,
Marius Linguraru,
Jake Albrecht,
Benedikt Wiestler,
Florian Kofler,
Anastasia Janas,
Dominic LaBella
, et al. (26 additional authors not shown)
Abstract:
Gliomas are the most common type of primary brain tumors. Although gliomas are relatively rare, they are among the deadliest types of cancer, with a survival rate of less than 2 years after diagnosis. Gliomas are challenging to diagnose, hard to treat and inherently resistant to conventional therapy. Years of extensive research to improve diagnosis and treatment of gliomas have decreased mortality…
▽ More
Gliomas are the most common type of primary brain tumors. Although gliomas are relatively rare, they are among the deadliest types of cancer, with a survival rate of less than 2 years after diagnosis. Gliomas are challenging to diagnose, hard to treat and inherently resistant to conventional therapy. Years of extensive research to improve diagnosis and treatment of gliomas have decreased mortality rates across the Global North, while chances of survival among individuals in low- and middle-income countries (LMICs) remain unchanged and are significantly worse in Sub-Saharan Africa (SSA) populations. Long-term survival with glioma is associated with the identification of appropriate pathological features on brain MRI and confirmation by histopathology. Since 2012, the Brain Tumor Segmentation (BraTS) Challenge have evaluated state-of-the-art machine learning methods to detect, characterize, and classify gliomas. However, it is unclear if the state-of-the-art methods can be widely implemented in SSA given the extensive use of lower-quality MRI technology, which produces poor image contrast and resolution and more importantly, the propensity for late presentation of disease at advanced stages as well as the unique characteristics of gliomas in SSA (i.e., suspected higher rates of gliomatosis cerebri). Thus, the BraTS-Africa Challenge provides a unique opportunity to include brain MRI glioma cases from SSA in global efforts through the BraTS Challenge to develop and evaluate computer-aided-diagnostic (CAD) methods for the detection and characterization of glioma in resource-limited settings, where the potential for CAD tools to transform healthcare are more likely.
△ Less
Submitted 30 May, 2023;
originally announced May 2023.
-
The Brain Tumor Segmentation (BraTS) Challenge 2023: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)
Authors:
Anahita Fathi Kazerooni,
Nastaran Khalili,
Xinyang Liu,
Debanjan Haldar,
Zhifan Jiang,
Syed Muhammed Anwar,
Jake Albrecht,
Maruf Adewole,
Udunna Anazodo,
Hannah Anderson,
Sina Bagheri,
Ujjwal Baid,
Timothy Bergquist,
Austin J. Borja,
Evan Calabrese,
Verena Chung,
Gian-Marco Conte,
Farouk Dako,
James Eddy,
Ivan Ezhov,
Ariana Familiar,
Keyvan Farahani,
Shuvanjan Haldar,
Juan Eugenio Iglesias,
Anastasia Janas
, et al. (48 additional authors not shown)
Abstract:
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20\%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The MICCA…
▽ More
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20\%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The MICCAI Brain Tumor Segmentation (BraTS) Challenge is a landmark community benchmark event with a successful history of 12 years of resource creation for the segmentation and analysis of adult glioma. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge, which represents the first BraTS challenge focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The BraTS-PEDs 2023 challenge focuses on benchmarking the development of volumentric segmentation algorithms for pediatric brain glioma through standardized quantitative performance evaluation metrics utilized across the BraTS 2023 cluster of challenges. Models gaining knowledge from the BraTS-PEDs multi-parametric structural MRI (mpMRI) training data will be evaluated on separate validation and unseen test mpMRI dataof high-grade pediatric glioma. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors.
△ Less
Submitted 23 May, 2024; v1 submitted 26 May, 2023;
originally announced May 2023.
-
The Brain Tumor Segmentation (BraTS) Challenge 2023: Brain MR Image Synthesis for Tumor Segmentation (BraSyn)
Authors:
Hongwei Bran Li,
Gian Marco Conte,
Syed Muhammad Anwar,
Florian Kofler,
Ivan Ezhov,
Koen van Leemput,
Marie Piraud,
Maria Diaz,
Byrone Cole,
Evan Calabrese,
Jeff Rudie,
Felix Meissen,
Maruf Adewole,
Anastasia Janas,
Anahita Fathi Kazerooni,
Dominic LaBella,
Ahmed W. Moawad,
Keyvan Farahani,
James Eddy,
Timothy Bergquist,
Verena Chung,
Russell Takeshi Shinohara,
Farouk Dako,
Walter Wiggins,
Zachary Reitman
, et al. (43 additional authors not shown)
Abstract:
Automated brain tumor segmentation methods have become well-established and reached performance levels offering clear clinical utility. These methods typically rely on four input magnetic resonance imaging (MRI) modalities: T1-weighted images with and without contrast enhancement, T2-weighted images, and FLAIR images. However, some sequences are often missing in clinical practice due to time const…
▽ More
Automated brain tumor segmentation methods have become well-established and reached performance levels offering clear clinical utility. These methods typically rely on four input magnetic resonance imaging (MRI) modalities: T1-weighted images with and without contrast enhancement, T2-weighted images, and FLAIR images. However, some sequences are often missing in clinical practice due to time constraints or image artifacts, such as patient motion. Consequently, the ability to substitute missing modalities and gain segmentation performance is highly desirable and necessary for the broader adoption of these algorithms in the clinical routine. In this work, we present the establishment of the Brain MR Image Synthesis Benchmark (BraSyn) in conjunction with the Medical Image Computing and Computer-Assisted Intervention (MICCAI) 2023. The primary objective of this challenge is to evaluate image synthesis methods that can realistically generate missing MRI modalities when multiple available images are provided. The ultimate aim is to facilitate automated brain tumor segmentation pipelines. The image dataset used in the benchmark is diverse and multi-modal, created through collaboration with various hospitals and research institutions.
△ Less
Submitted 28 June, 2023; v1 submitted 15 May, 2023;
originally announced May 2023.
-
The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) MRI Dataset
Authors:
Jeffrey D. Rudie,
Rachit Saluja,
David A. Weiss,
Pierre Nedelec,
Evan Calabrese,
John B. Colby,
Benjamin Laguna,
John Mongan,
Steve Braunstein,
Christopher P. Hess,
Andreas M. Rauschecker,
Leo P. Sugrue,
Javier E. Villanueva-Meyer
Abstract:
The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) dataset is a public, clinical, multimodal brain MRI dataset consisting of 560 brain MRIs from 412 patients with expert annotations of 5136 brain metastases. Data consists of registered and skull stripped T1 post-contrast, T1 pre-contrast, FLAIR and subtraction (T1 pre-contrast - T1 post-contrast) imag…
▽ More
The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) dataset is a public, clinical, multimodal brain MRI dataset consisting of 560 brain MRIs from 412 patients with expert annotations of 5136 brain metastases. Data consists of registered and skull stripped T1 post-contrast, T1 pre-contrast, FLAIR and subtraction (T1 pre-contrast - T1 post-contrast) images and voxelwise segmentations of enhancing brain metastases in NifTI format. The dataset also includes patient demographics, surgical status and primary cancer types. The UCSF-BSMR has been made publicly available in the hopes that researchers will use these data to push the boundaries of AI applications for brain metastases. The dataset is freely available for non-commercial use at https://imagingdatasets.ucsf.edu/dataset/1
△ Less
Submitted 30 May, 2024; v1 submitted 14 April, 2023;
originally announced April 2023.
-
Federated Learning Enables Big Data for Rare Cancer Boundary Detection
Authors:
Sarthak Pati,
Ujjwal Baid,
Brandon Edwards,
Micah Sheller,
Shih-Han Wang,
G Anthony Reina,
Patrick Foley,
Alexey Gruzdev,
Deepthi Karkada,
Christos Davatzikos,
Chiharu Sako,
Satyam Ghodasara,
Michel Bilello,
Suyash Mohan,
Philipp Vollmuth,
Gianluca Brugnara,
Chandrakanth J Preetha,
Felix Sahm,
Klaus Maier-Hein,
Maximilian Zenk,
Martin Bendszus,
Wolfgang Wick,
Evan Calabrese,
Jeffrey Rudie,
Javier Villanueva-Meyer
, et al. (254 additional authors not shown)
Abstract:
Although machine learning (ML) has shown promise in numerous domains, there are concerns about generalizability to out-of-sample data. This is currently addressed by centrally sharing ample, and importantly diverse, data from multiple sites. However, such centralization is challenging to scale (or even not feasible) due to various limitations. Federated ML (FL) provides an alternative to train acc…
▽ More
Although machine learning (ML) has shown promise in numerous domains, there are concerns about generalizability to out-of-sample data. This is currently addressed by centrally sharing ample, and importantly diverse, data from multiple sites. However, such centralization is challenging to scale (or even not feasible) due to various limitations. Federated ML (FL) provides an alternative to train accurate and generalizable ML models, by only sharing numerical model updates. Here we present findings from the largest FL study to-date, involving data from 71 healthcare institutions across 6 continents, to generate an automatic tumor boundary detector for the rare disease of glioblastoma, utilizing the largest dataset of such patients ever used in the literature (25,256 MRI scans from 6,314 patients). We demonstrate a 33% improvement over a publicly trained model to delineate the surgically targetable tumor, and 23% improvement over the tumor's entire extent. We anticipate our study to: 1) enable more studies in healthcare informed by large and diverse data, ensuring meaningful results for rare diseases and underrepresented populations, 2) facilitate further quantitative analyses for glioblastoma via performance optimization of our consensus model for eventual public release, and 3) demonstrate the effectiveness of FL at such scale and task complexity as a paradigm shift for multi-site collaborations, alleviating the need for data sharing.
△ Less
Submitted 25 April, 2022; v1 submitted 22 April, 2022;
originally announced April 2022.
-
The Brain Tumor Sequence Registration (BraTS-Reg) Challenge: Establishing Correspondence Between Pre-Operative and Follow-up MRI Scans of Diffuse Glioma Patients
Authors:
Bhakti Baheti,
Satrajit Chakrabarty,
Hamed Akbari,
Michel Bilello,
Benedikt Wiestler,
Julian Schwarting,
Evan Calabrese,
Jeffrey Rudie,
Syed Abidi,
Mina Mousa,
Javier Villanueva-Meyer,
Brandon K. K. Fields,
Florian Kofler,
Russell Takeshi Shinohara,
Juan Eugenio Iglesias,
Tony C. W. Mok,
Albert C. S. Chung,
Marek Wodzinski,
Artur Jurgas,
Niccolo Marini,
Manfredo Atzori,
Henning Muller,
Christoph Grobroehmer,
Hanna Siebert,
Lasse Hansen
, et al. (48 additional authors not shown)
Abstract:
Registration of longitudinal brain MRI scans containing pathologies is challenging due to dramatic changes in tissue appearance. Although there has been progress in developing general-purpose medical image registration techniques, they have not yet attained the requisite precision and reliability for this task, highlighting its inherent complexity. Here we describe the Brain Tumor Sequence Registr…
▽ More
Registration of longitudinal brain MRI scans containing pathologies is challenging due to dramatic changes in tissue appearance. Although there has been progress in developing general-purpose medical image registration techniques, they have not yet attained the requisite precision and reliability for this task, highlighting its inherent complexity. Here we describe the Brain Tumor Sequence Registration (BraTS-Reg) challenge, as the first public benchmark environment for deformable registration algorithms focusing on estimating correspondences between pre-operative and follow-up scans of the same patient diagnosed with a diffuse brain glioma. The BraTS-Reg data comprise de-identified multi-institutional multi-parametric MRI (mpMRI) scans, curated for size and resolution according to a canonical anatomical template, and divided into training, validation, and testing sets. Clinical experts annotated ground truth (GT) landmark points of anatomical locations distinct across the temporal domain. Quantitative evaluation and ranking were based on the Median Euclidean Error (MEE), Robustness, and the determinant of the Jacobian of the displacement field. The top-ranked methodologies yielded similar performance across all evaluation metrics and shared several methodological commonalities, including pre-alignment, deep neural networks, inverse consistency analysis, and test-time instance optimization per-case basis as a post-processing step. The top-ranked method attained the MEE at or below that of the inter-rater variability for approximately 60% of the evaluated landmarks, underscoring the scope for further accuracy and robustness improvements, especially relative to human experts. The aim of BraTS-Reg is to continue to serve as an active resource for research, with the data and online evaluation tools accessible at https://bratsreg.github.io/.
△ Less
Submitted 17 April, 2024; v1 submitted 13 December, 2021;
originally announced December 2021.
-
The University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) Dataset
Authors:
Evan Calabrese,
Javier E. Villanueva-Meyer,
Jeffrey D. Rudie,
Andreas M. Rauschecker,
Ujjwal Baid,
Spyridon Bakas,
Soonmee Cha,
John T. Mongan,
Christopher P. Hess
Abstract:
Here we present the University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) dataset. The UCSF-PDGM dataset includes 500 subjects with histopathologically-proven diffuse gliomas who were imaged with a standardized 3 Tesla preoperative brain tumor MRI protocol featuring predominantly 3D imaging, as well as advanced diffusion and perfusion imaging techniques. The dataset al…
▽ More
Here we present the University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) dataset. The UCSF-PDGM dataset includes 500 subjects with histopathologically-proven diffuse gliomas who were imaged with a standardized 3 Tesla preoperative brain tumor MRI protocol featuring predominantly 3D imaging, as well as advanced diffusion and perfusion imaging techniques. The dataset also includes isocitrate dehydrogenase (IDH) mutation status for all cases and O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status for World Health Organization (WHO) grade III and IV gliomas. The UCSF-PDGM has been made publicly available in the hopes that researchers around the world will use these data to continue to push the boundaries of AI applications for diffuse gliomas.
△ Less
Submitted 15 March, 2022; v1 submitted 30 August, 2021;
originally announced September 2021.